Abstract:Paclitaxel (PTX), a typical chemotherapeutic agent, was restricted in clinical cancer treatment as its poor water solubility (-0.25 & mu;g/mL). This study firstly prepared the thioether-bridged polymer-drug conjugates HAACP and HPP based on hyaluronic acid (HA) to address the poor water solubility of PTX. After the structure confirmed by 1H NMR and MS, the biocompatibility of the conjugates was evaluated. The hydrolyzed profiles of thioether-bridged conjugates were also determined in H2O2 to release free PTX, indicating the particular release kinetic at the tumor microenvironment. The binding capacity between the conjugates and PTX was investigated by critical aggregation concentration (cac) as an attractive interaction, which further proved to be a strong syn-ergism when the mole fraction of PTX was less than or equal to 0.2. Nanoparticles HPP-PTX4 were demonstrated a largest solubility enhancement ratio (4338.49) of PTX than other nanoparticles, which indicated the effective solubilization (-1 mg/mL). Wound healing assays and cytotoxicity had been conducted to prove the inhibition of the nanoparticles for the cancer cells and non-toxic property for normal cells. Cellular uptake studies not only reflected the effective internalization of the nanoparticles, but also proved the HA-mediated active targeting behavior. The cell arrest mechanism for mitosis was evaluated by apoptosis and cell cycle assays and further apoptosis. 3D spheres models were established to mimic the tumor in vivo to investigate the inhibition and penetration capacity of the nanoparticles for cancer cells. In view of the experiments, we thought the synthesized conjugate could represent as the promising drug delivery for the hydrophobic drugs, and thus hold tremendous potentials for anti-tumor treatment.

Solubilization Methods for Paclitaxel and Docetaxel: An Overview

Advances in Drug Delivery Systems for Lipophilic Drug Paclitaxel: Developments, Challenges, and Opportunities (A Review)

Designing Paclitaxel Drug Delivery Systems Aimed at Improved Patient Outcomes: Current Status and Challenges

Novel formulations of taxanes: a review. Old wine in a new bottle?

Progress on the Prodrugs of Paclitaxel

Innovative strategies for effective paclitaxel delivery: Recent developments and prospects

Recent Progress of Paclitaxel Delivery Systems: Covalent and Noncovalent Approaches

Liposomal Nanoformulation-encapsulated Paclitaxel for Reducing Chemotherapy Side Effects in Lung Cancer Treatments: Recent Advances and Future Outlooks

Facile Preparation of Paclitaxel Nano-Suspensions to Treat Lung Cancer

A Study on Improving Bioavailability of Paclitaxel through different Novel Drug Delivery Approaches

Paclitaxel Drug Delivery Systems: Focus on Nanocrystals’ Surface Modifications

Characteristics, Properties and Analytical Methods of Paclitaxel: A Review

Synthesis of Ph-Sensitive, Water-Soluble Paclitaxel Prodrugs Based on Norbornene-Functional Polylactide by Copper-Free Click Chemistry

Progress of Clinical Research on New Nano-Drug Delivery System of Paclitaxel

Paclitaxel Solubilized Nanoparticles Based on Binding Affinity for Efficient Drug Delivery

Nanopaclitaxel therapy: an evidence based review on the battle for next-generation formulation challenges

Amphiphilic conjugates for solubilization of paclitaxel as efficient drug carriers based on hyaluronic acid and cyclodextrins

Efficient Drug Delivery of Paclitaxel Glycoside: A Novel Solubility Gradient Encapsulation into Liposomes Coupled with Immunoliposomes Preparation

A High Capacity Polymeric Micelle of Paclitaxel: Implication of High Dose Drug Therapy to Safety and in Vivo Anti-Cancer Activity

Near-Critical Fluid Micellization for High and Efficient Drug Loading: Encapsulation of Paclitaxel into Peg-B-Pcl Micelles

Preparation and studies of docetaxel proliposome